Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990–2017

Chen, Zhilin; Xu, Lei; Shi, Wenjie; Zeng, Fang; Zhuo, Rui; Hao, Xinbao; Fan, Pingming

doi:10.1007/s10549-020-05561-1

Cited by 111 publications

(96 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar observation has been reported in a study by Saggu et al, based on 15 years (1990-2014) data obtained from the Saudi cancer registry. This is also reported, worldwide, in most countries mainly in developing countries, as shown in a recent study by [15] (based on data collected between 1990 -2017), revealed that female breast cancers increased from 870.2 thousand to 1937.6 thousand, with age-standardized incidence rate increased from 39.2/100,000 to 45.9/100,000, mainly found in developing countries, however, many developed countries (like USA and UK) showed decrease in incidence rate.…”

Section: The Distribution Of Patients Among the Different Cities Is Lsupporting

confidence: 80%

Correlation of Breast cancer Prognostic and Predictive indicators in Saudi patients: A 20 years retrospective observational study

Kussaibi

2020

Preprint

View full text Add to dashboard Cite

Introduction Breast cancer is the most common cancer in women in Saudi Arabia and the world (WHO 2020). Several studies have been published, worldwide, about the prognostic indicators of breast cancer, many of them showed a characteristic distribution according to certain geographical areas Methods Over 20 years (1998-2018), the results of 498 patients diagnosed with breast cancer, have been collected from the archive of the pathology department at King Fahd University Hospital (KFHU). Results This study included 498 patients diagnosed with breast cancer at King Fahd University Hospital over 20 years period (1998-2018), 58.4% (n=291) were Saudis. Data analysis showed a wide age distribution of breast cancers among eastern Saudi patients; however, most cases were seen in the 3rd and 4th decades. Luminal B was the most common subtype followed by triple-negative and luminal-A. Statistical analysis revealed a significant negative relationship between Saudi patients' age at diagnosis and Her2 expression (P= .030), interestingly, this association was not significant in none-Saudi patients (P= .528). Discussion/Conclusion. Our data revealed that breast cancer in Eastern Province had similar prognostics to international findings, however, Her2 profile and molecular subtype among Eastern Saudi women showed a minor deviation from worldwide published data.

show abstract

Section: The Distribution Of Patients Among the Different Cities Is Lsupporting

confidence: 80%

Correlation of Breast cancer Prognostic and Predictive indicators in Saudi patients: A 20 years retrospective observational study

Kussaibi

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…A sign of statistical significance is that the P-value is less than 0.05. 39,40 3 | RESULTS Table 1). The ASIR of esophageal cancer varies considerably across the world, with the highest ASIR observed in Malawi (23.0 per 100 000 in 2017), followed by Mongolia and Swaziland ( Figure 1A).…”

Section: Discussionmentioning

confidence: 99%

Global trends in the incidence and mortality of esophageal cancer from 1990 to 2017

et al. 2020

View full text Add to dashboard Cite

Background The incidence and mortality of esophageal cancer are high, with 5.90 new cases and 5.48 deaths per 100 000 people worldwide in 2017. The prognosis of esophageal cancer is poor, with an overall 5‐year survival rate of less than 20%. Esophageal cancer in different geographical locations has different etiologies, and the incidence and mortality of esophageal cancer continue to rise in some regions. Methods We collected incidence and mortality data by age and gender for 195 countries and territories from 1990 to 2017 in the Global Burden of Disease (GBD) database. And we used these data to calculate the estimated annual percentage change (EAPC) to quantify trends in morbidity and mortality. Then we analyzed the gender‐ and age‐specific incidence and mortality in esophageal cancer to targeted high‐risk populations. Finally, we analyzed the correlation between the age‐standardized mortality rate (ASMR) and both the EAPC and social‐demographic index (SDI), and we calculated the Pearson correlation coefficient. Results We found that Malawi, East Asia, and high‐middle SDI regions had the highest age‐standardized incidence rate (ASIR) and ASMR, and the ASIR and ASMR in western Sub‐Saharan Africa showed an upward trend. Our study also showed that the incidence and mortality in esophageal cancer were highest in men and in the 70+ years age group, and they presented a decreasing trend in most regions, but the 15‐49 years age groups in Australasia, Caribbean, and Oceania and the 70+ years age group in High‐Income North America, Oceania and high‐SDI regions presented an increasing trend. There were significant negative associations between ASMR at baseline and EAPC and between ASMR and SDI in 2017. Conclusion By analyzing the global distribution of incidence and mortality in esophageal cancer, trends over time, and gender and age specificity, we can understand the heterogeneity of its global trends. This heterogeneity can help us to identify high‐risk groupsand to provide clues for the exploration of the etiology and early prevention of the disease.

show abstract

“…BC cells with a density of 2×10 3 were routinely inoculated into 96-well plates, and were added with trastuzumab of different concentrations 24 hours later. The sensitivity of the cells to BC was detected by CCK8 method 72 hours later, and the IC50 was calculated.…”

Section: Drug Sensitivity Testmentioning

confidence: 99%

“…1,2 In the United States, BC accounted for 30% of all new cancers in 2017. 3 Although advances in early diagnosis, surgery, chemotherapy, and other treatment methods have greatly improved the prognosis of BC patients, the survival of them is still not optimistic due to the high heterogeneity of BC cells and the increasing resistance of tumor cells to chemotherapeutic drugs. 4 Therefore, the call for understanding the mechanism of BC development and the development of drug resistance, and finding more targets for treating BC is overwhelmingly urgent.…”

Section: Introductionmentioning

confidence: 99%

<p>LncRNA-SNHG7 Enhances Chemotherapy Resistance and Cell Viability of Breast Cancer Cells by Regulating miR-186</p>

Zhang

Kang

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: Clinical tolerance to trastuzumab greatly affects the therapeutic effect in breast cancer (BC). Long-chain non-coding RNA (lncRNA) plays an important role in the development of trastuzumab resistance, in which SNHG7 can promote the epithelial mesenchymal transformation (EMT) of breast cancer cells into, while EMT is related to trastuzumab resistance of breast cancer cells. Objective: To investigate whether lncRNA-SNHG7 can enhance chemotherapy resistance and cell viability of BC cells by regulating miR-186. Methods: SK-BR-3 and SNHG7 of HER2+BC cells were induced to enhance the resistance of BC cells to trastuzumab by regulating miR-186, and to regulate the expression levels of SNHG7 and miR-186. The sensitivity of drug-resistant cells to trastuzumab and the changes of cell proliferation, migration, apoptosis, and EMT were measured and verified by tumorigenesis in vivo. The effects of miR-186 on SNHG7 were investigated through rescue experiments; the regulatory relationship between the expression of SNHG7 and miR-186 was verified by the double luciferase reporter (DLR) and the mechanism of SNHG7 was explored. Results: Down-regulation of SNHG7 or up-regulation of miR-186 could increase the sensitivity of BC cells to trastuzumab, inhibit the proliferation, migration and EMT, and promote apoptosis. Compared with the down-regulation of SNHG7 or miR-186 alone, simultaneous down-regulation of SNHG7 and miR-186 on drug-resistant cells brought notably lower sensitivity to trastuzumab and apoptosis rate, and higher proliferation and apoptosis ability. The DLR showed that miR-186 could specifically inhibit the expression of SNHG7. The results of tumorigenesis in vivo revealed that down-regulation of SNHG7 or up-regulation of miR-186 could improve the therapeutic effect of trastuzumab and reduce the tumor volume, and miR-186 could also antagonize the effect of SNHG7. Conclusion: Down-regulation of SNHG7-targeted miR-186 can reverse trastuzumab resistance of BC cells, inhibit the proliferation, migration, and EMT levels of BC cells, and promote apoptosis.

show abstract

Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990–2017

Cited by 111 publications

References 43 publications

Correlation of Breast cancer Prognostic and Predictive indicators in Saudi patients: A 20 years retrospective observational study

Correlation of Breast cancer Prognostic and Predictive indicators in Saudi patients: A 20 years retrospective observational study

Global trends in the incidence and mortality of esophageal cancer from 1990 to 2017

<p>LncRNA-SNHG7 Enhances Chemotherapy Resistance and Cell Viability of Breast Cancer Cells by Regulating miR-186</p>

Contact Info

Product

Resources

About